Zealand Pharma Zeydovio EU CHMP Backing
Analysis based on 6 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026
The CHMP positive opinion materially de-risks Zeydovio's European path to market, strengthening Zealand Pharma's revenue outlook and its leverage in ongoing global partnership negotiations, which should support the stock. Broader market impact is limited to the rare-disease and GLP-2 peptide space, with modest read-through for European biotech sentiment and no meaningful macro effect.
Zealand Pharma announced on September 18, 2026 that the European Union — European Medicines Agency's European Union — Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Zeydovio (glepaglutide) for the treatment of adults with short bowel syndrome (SBS). The recommendation was supported by data from the Phase 3 EASE-1 trial, in which twice-weekly glepaglutide reduced parenteral support requirements compared with placebo: 65.7% of treated patients achieved at least a 20% reduction in weekly parenteral support volume versus 38.9% on placebo, and five patients (14%) were completely weaned off parenteral support, while no placebo patients achieved this. Glepaglutide is a long-acting GLP-2 analogue administered twice weekly via a single-dose autoinjector. The International — European Commission will now review the opinion, with a final marketing authorization decision expected within approximately 67 days; if approved, the authorization would be valid across all European Union member states as well as Iceland, Liechtenstein, and Norway. Zealand Pharma said it is stepping up talks to find a global commercial partner responsible for the drug's launch in Europe and the United States, and is enrolling patients in the Phase 3 EASE-5 trial to support a US New Drug Application. The US United States — Food and Drug Administration has granted orphan drug designation to glepaglutide for short bowel syndrome. The positive opinion marks the first major advancement in SBS treatment in Europe in more than a decade, according to the company.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard